» Articles » PMID: 26455908

Downregulation of Nitrogen Permease Regulator Like-2 Activates PDK1-AKT1 and Contributes to the Malignant Growth of Glioma Cells

Overview
Journal Mol Carcinog
Date 2015 Oct 13
PMID 26455908
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Nitrogen permease regulator like-2(NPRL2) is a candidate tumor suppressor gene(TSG) located on chromosome 3p21.3 and deletions frequently occur in this region, leading to canceration. Recently, molecular pathologic researches have provided valuable insights into the downregulation of NPRL2 in carcinogenesis in some types of cancers. However, very little is known about genetic changes of NPRL2 involved in glioma. Here, for the first time, we aimed to understand the expression levels, functions and mechanisms of NPRL2 for progression of glioma. We clearly demonstrated that NPRL2 expression was decreased in glioma and was negatively correlated with the histologic grade. The upregulation of NPRL2 expression in glioma cells inhibited proliferation by inducing G0/G1 cell cycle arrest in vitro and suppressed the growth of xenotransplanted tumors. In contrast, siRNA-mediated knockdown of NPRL2 promoted glioma growth. The anti-cancer effects of NPRL2 were involved in dephosphorylation of PDK1 and downstream AKT1 resulting in inactivation of the PDK1-AKT1 signaling pathway, this ultimately increased the expression of p21 and p27, and inactivated CDK2 and CDK4. Our data confirmed NPRL2 was downregulated in gliomas. More importantly, NPRL2 was able to inhibit cell proliferation in vitro and repress tumorigenicity in vivo, suggesting its role as a tumor suppressor. Our data provide a basis for the further development of a promising therapeutic target for glioma. © 2015 Wiley Periodicals, Inc.

Citing Articles

gene therapy induces effective antitumor immunity in mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model.

Meraz I, Majidi M, Song R, Meng F, Gao L, Wang Q Elife. 2025; 13.

PMID: 39932765 PMC: 11813225. DOI: 10.7554/eLife.98258.


NPRL2 promotes TRIM16-mediated ubiquitination degradation of Galectin-3 to prevent CD8T lymphocyte cuproptosis in glioma.

Wang F, Yue J, Zhang M, Sun M, Luo X, Zhang H Cell Mol Life Sci. 2024; 81(1):424.

PMID: 39367988 PMC: 11456027. DOI: 10.1007/s00018-024-05454-2.


Bioinformatics analysis of the prognostic and immunotherapeutic significance of NPRL2 in stomach adenocarcinoma.

Pi Y, Zhan Y, Song J, Jin X, Chen J J Gastrointest Oncol. 2022; 13(4):1589-1604.

PMID: 36092347 PMC: 9459220. DOI: 10.21037/jgo-22-115.


New Insights into LINC00346 and its Role in Disease.

Lu J, Xiao Z, Xu M, Li L Front Cell Dev Biol. 2022; 9:819785.

PMID: 35096842 PMC: 8794746. DOI: 10.3389/fcell.2021.819785.


Intracellular and extracellular S100A9 trigger epithelial-mesenchymal transition and promote the invasive phenotype of pituitary adenoma through activation of AKT1.

Huang N, Zhao G, Yang Q, Tan J, Tan Y, Zhang J Aging (Albany NY). 2020; 12(22):23114-23128.

PMID: 33203795 PMC: 7746360. DOI: 10.18632/aging.104072.